Merck KGaA (OTCMKTS:MKKGY) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Merck KGaA (OTCMKTS:MKKGY) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday,Zacks reports.

Separately, UBS Group lowered shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Six analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Merck KGaA Trading Up 0.3%

Shares of MKKGY opened at $33.84 on Tuesday. The business’s 50-day moving average price is $31.71 and its 200-day moving average price is $30.07. Merck KGaA has a twelve month low of $23.73 and a twelve month high of $34.19. The stock has a market cap of $21.87 billion, a PE ratio of 17.44, a P/E/G ratio of 2.92 and a beta of 0.92. The company has a quick ratio of 1.09, a current ratio of 1.69 and a debt-to-equity ratio of 0.37.

Merck KGaA Company Profile

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.